Healthcare
Pharvaris N.V.(PHVS)
Live Price
Offline$32.80
-1.83% today
Window Change
+8.75%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $1.64B
- Revenue Growth
- 0.0%
- EPS Growth
- -19.8%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharvaris N.V. (PHVS) is a Healthcare stock with a market cap of $1.64B and listed on NASDAQ. The stock last traded around $32.80 and up 8.8% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -19.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -19.8%, free cash flow -13.7% with operating margin 0.0% and ROIC -31.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHVS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -19.8%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHVS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHVS Max Drawdown
-4.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHVS and SPY.
Company Overview
Pharvaris N.V.
NASDAQ Global Select
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
- Leadership
- Berndt Axel Edvard Modig
- IPO Date
- Feb 5, 2021
- Employees
- 108
- Street Address
- J.H. Oortweg 21
- Mailing
- Leiden, 2333 CH
- Region
- Leiden, NL
- Reporting Currency
- USD
- Investor Line
- 31 71 203 6410
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.5
Growth
- Revenue
- 0.0%
- EPS
- -19.8%
- Free Cash Flow
- -13.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -70.8%
- ROIC
- -31.4%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 10.11
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.